No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up-Reference-Cited by-同舟云学术

No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up

Published:2019-12-26 Issue:4 Volume:52 Page:249-256
ISSN:2374-4235
Container-title:Infectious Diseases
language:en
Short-container-title:Infectious Diseases

Author:

Calza Leonardo¹,Borderi Marco¹,Colangeli Vincenzo¹,Borioni Aurora¹,Coladonato Simona¹,Granozzi Bianca¹,Viale Pierluigi¹

Affiliation:

1. Department of Medical and Surgical Sciences, Section of Infectious Diseases, “Alma Mater Studiorum”, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy

Publisher

Informa UK Limited

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23744235.2019.1707279

Reference37 articles.

1. Excess Mortality in Patients with AIDS in the Era of Highly Active Antiretroviral Therapy: Temporal Changes and Risk Factors

2. Inflammation, immune activation, and cardiovascular disease in HIV

3. Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults

4. Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013

5. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors;BMC Infectious Diseases;2024-09-09

2. Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study;PLOS ONE;2020-08-20